Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxycycline Pharmacokinetics and Adherence Post-Single and Repeat Dosing Schemas
NCT07755618Phase 1Enrolling by invitation
- Sponsor
- HIV Prevention Trials Network
- Start
- Aug 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of doxycycline in sexually transmitted infection (STI) (4 arms), sponsored by HIV Prevention Trials Network. Primary endpoints: Maximum observed plasma concentration at 336 hours, Minimum observed plasma concentration at 336 hours and 4 more. Started Aug 2026; status: enrolling by invitation.
02
Drugs
doxycycline
03
Conditions
sexually transmitted infection (STI)
Beyond the preview
Go deeper on NCT07755618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07755618.